MemphasysASX:MEM Pretax Margin % is -19,491.67% as of Dec. 2025. The stock has 5 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Memphasys ranks worse than 99.27% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Memphasys's Pre-Tax Income for the
six
months ended in Dec. 2025 was A$-2.34 Mil. Memphasys's Revenue for the
six
months ended in Dec. 2025 was A$0.01 Mil. Therefore, Memphasys's pretax margin for the quarter that ended in Dec. 2025 was -19,491.67%.
The historical rank and industry rank for Memphasys's Pretax Margin % or its related term are showing as below:
ASX:MEM'
s Pretax Margin % Range Over the Past 10 Years
Min: -125975 Med: -7711.11 Max: -3717.19
Current: -36758.33
ASX:MEM's Pretax Margin % is ranked worse than 99.27% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.61
vs ASX:MEM: -36758.33
Memphasys (ASX:MEM) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Memphasys Pretax Margin % Related Terms
Memphasys Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Memphasys's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:MEM vs ABT, SYK, MDT: Pretax Margin % Comparison
For the Medical Devices subindustry, Memphasys's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Memphasys Pretax Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Memphasys's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Memphasys's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Memphasys (ASX:MEM) has a Pretax Margin % of -19,491.67% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Memphasys and its competitors. According to the industry distribution chart, Memphasys ranks #811 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 99.3%.
Is Memphasys' Pretax Margin % too high?
Memphasys' current Pretax Margin % is -19,491.67%. Based on the distribution chart, Memphasys ranks #811 out of 817 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Memphasys' Pretax Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Memphasys ranks #811 out of 817 companies for Pretax Margin %. This places Memphasys in the lower half of its industry. The industry median Pretax Margin % is 2.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Devices & Instruments company?
The median Pretax Margin % among Medical Devices & Instruments companies is 2.61, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Memphasys and its competitors. For the Medical Devices & Instruments industry, the median Pretax Margin % is 2.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Memphasys's current Pretax Margin % is -19,491.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Memphasys stock overvalued right now?
Memphasys (ASX:MEM) has a current Pretax Margin % of -19,491.67%. The current Pretax Margin % is -19,491.67%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Memphasys (ASX:MEM), the current Pretax Margin % is -19,491.67% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Memphasys Ltd is an Australian reproductive biotechnology company developing and commercializing novel reproduction and fertility solutions for humans and animals. The products in its development pipeline include a range of devices, media, and in vitro diagnostic solutions. The company is currently focused on the commercialisation of its patented Felix System, a novel bio-separation technology for assisted reproduction, designed to revolutionise sperm separation in assisted reproductive technology (ART) by providing a rapid, gentle, and automated process. The group has only one operating segment, being Reproductive Technologies, the assets and liabilities of which are located in Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MEM has been successfully added to your 